Spoken Alpha
Arbutus Biopharma Corp
Arbutus Biopharma develops clinical-stage therapies for chronic hepatitis B, including imdusiran, an RNA interference therapeutic designed to suppress hepatitis B virus, and AB-101, an oral immune checkpoint inhibitor.
Arbutus Biopharma Corp is a Healthcare company operating in Biotechnology with a $997.5M market cap.
ABUS beat consensus EPS by 0.0% in Q2 FY2026, reported Aug 11, 2026.
15 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ABUS.
$ curl https://api.spokenalpha.com/v1/companies/ABUSFAQ
Spoken Alpha indexes ABUS's earnings call transcripts at https://spokenalpha.com/companies/ABUS. Each call links to attributed speakers and parsed analyst Q&A.
Arbutus Biopharma Corp (ABUS) held its most recent earnings call on 2024-11-06, covering fiscal Q3 2024.
Arbutus Biopharma Corp (ABUS) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | $-0.03 | $-0.03 | 0.0% | $1.0M | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $1.19 | $-0.05 | +100.0% | $179.1M | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $-0.01 | $-0.03 | +54.3% | $1.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.06 | $-0.05 | -20.0% | $529.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $0.01 | $-0.09 | +100.0% | $10.7M | — | — | EODHD |
| Q1 FY2025 | 2025-05-13 | $-0.18 | $-0.15 | -20.0% | $1.8M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.10 | $-0.12 | +14.5% | $1.6M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.14 | $-0.13 | -7.7% | $1.3M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.15 | $-0.13 | -15.4% | $1.7M | — | — | EODHD |
| Q1 FY2024 | 2024-05-01 | $-0.14 | $-0.15 | +6.7% | $1.5M | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $-0.12 | $-0.12 | 0.0% | $2.1M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.16 | $-0.15 | -6.7% | $4.7M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.13 | $-0.14 | +7.1% | $4.7M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.14 | $-0.18 | +22.2% | $6.7M | — | — | EODHD |
| Q4 FY2022 | 2023-03-01 | $-0.14 | $-0.13 | -7.7% | $6.2M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.16 | $-0.18 | +11.1% | $6.0M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-0.13 | $-0.15 | +13.3% | $14.2M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-0.14 | $-0.20 | +30.0% | $12.6M | — | — | EODHD |
| Q4 FY2021 | 2022-03-02 | $-0.15 | $-0.19 | +21.1% | $3.2M | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $-0.30 | $-0.29 | -3.5% | $3.3M | — | — | EODHD |
Source: EODHD. ABUS reported actuals as published; sparse fields render as —.